Edgar Filing: BIOTECH TARGET N V - Form 4

BIOTECH 7	FARGET N V									
Form 4										
December 2	6, 2018									
FORM	14							OMB AF	PROVAL	
	UNITED	STATES SEC V	URITIES Vashingtor			NGE CO	OMMISSION	OMB Number:	3235-0287	
Check th								Expires:	January 31, 2005	
	if no longer subject to STATEMENT OF CHAN			IGES IN BENEFICIAL OWNE				RSHIP OF Estimated ave		
Section		SECURITIES						burden hours per		
Form 4 o Form 5	-		-16(a) = 54	ha Caarai	i a T		A at af 1024	response	0.5	
obligatio		suant to Sectio				-	Act of 1934, 1935 or Section			
may con	unue.	30(h) of the	•	•	· ·	•				
See Instr 1(b).	ruction	50(ii) of the	mvestmen	n compa	1y 7 10		,			
1(0).										
(Print or Type	Responses)									
1. Name and Address of Reporting Person *2. IssueBIOTECH TARGET N VSymbol				8			5. Relationship of Reporting Person(s) to Issuer			
•			rion Theraj	peutics, In	c. [E	SPR]	(Check all applicable)			
(Last)	(First) (I	Middle) 3. Dat	e of Earliest '	of Earliest Transaction			(Check an applicable)			
			h/Day/Year)				Director	_X_ 10%	Owner	
			4/2018				Officer (give title Other (specify below)			
	(Street)	4. If A	mendment, I	endment, Date Original			6. Individual or Joint/Group Filing(Check			
Filed(Mo			Month/Day/Ye	ar)			Applicable Line)			
	D0 00000						Form filed by On _X_ Form filed by M			
CURACAC), P8 00000						Person		1 0	
(City)	(State)	(Zip) T	able I - Non	Derivative	Secur	rities Acqu	ired, Disposed of,	or Beneficial	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Yea	Code	4. Securiti ord Dispose (Instr. 3, 4	ed of (and 5		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	12/24/2018		Р	50,000	A	\$ 39.9145	3,392,964	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIOTECH TARC	GET N V - Form 4
----------------------------	------------------

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	of	vative rities uired or osed)) r. 3,	Expiration Date (Month/Day/Year) e		Amou Under Secur	le and unt of rlying rities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Addro	ess	Relationships								
1	Director	10% Owner	Officer	Other						
BIOTECH TARGET N V SNIPWEG 26 CURACAO, P8 00000		Х								
BB BIOTECH AG SCHWERTSTRASSE 6 SCHAFFHAUSEN, V8 CH-8	3200	Х								
Signatures										
/s/ Ivo Betschart	12/25/2018									
<u>**</u>Signature of Reporting Person	Date									

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.